How should hospital procurement teams evaluate LC-MS/MS versus immunoassay platforms for their TDM programs?

LC-MS/MS offers superior specificity and multi-analyte capability but demands higher capital outlay and skilled operators. Immunoassays suit high-volume, single-analyte workflows with faster turnaround. Choose based on test-menu complexity and available staffing [10]. Read More

What reimbursement risks should investors weigh when assessing the Therapeutic Drug Monitoring Market?

Payer coverage for newer biologics-monitoring panels remains inconsistent, with only 38% of U.S. commercial plans covering infliximab trough testing in 2024. Reimbursement expansion timelines vary by geography and drug class [9]. Read More

How do continuous biosensors differ from traditional blood-draw-based TDM in clinical workflow impact?

Biosensors deliver real-time concentration data through wearable patches, eliminating phlebotomy scheduling and enabling same-day dose adjustments. They reduce clinic visits but require new data-integration pathways with EHR systems [6]. Read More

Which emerging drug classes are most likely to expand the Therapeutic Drug Monitoring Market test menu by 2030?

Bispecific antibodies and antibody-drug conjugates with steep dose-exposure curves are leading candidates. CAR-T persistence monitoring is also generating early clinical demand for novel assay development [13]. Read More

What role does pharmacogenomic testing play alongside traditional drug-level monitoring?

Pharmacogenomic results inform initial dose selection, while TDM confirms that achieved concentrations match therapeutic targets. Combined use reduces trial-and-error dosing cycles by roughly 20% in transplant settings [1]. Read More

How are decentralized clinical trials reshaping demand for remote sample-collection TDM kits?

Sponsors increasingly require home-collected dried-blood-spot samples shipped to central labs for pharmacokinetic endpoints. This shift creates new consumable revenue outside traditional hospital procurement channels [7]. Read More

What competitive moats differentiate leading players in the Therapeutic Drug Monitoring Market?

Installed analyzer bases create reagent lock-in, and proprietary assay menus for niche analytes build switching costs. Companies adding AI-dosing software deepen workflow integration beyond commodity testing [15]. Read More

Therapeutic Drug Monitoring Market (2026 - 2035)

Therapeutic Drug Monitoring Market Research Report: Size, Share, Trend Analysis By Applications (Oncology, Cardiology, Neurology, Infectious Diseases, Transplantation), By Technology (Immunoassays, Chromatography, Mass Spectrometry, PCR, Microfluidics), By End Users (Hospitals, Diagnostic Laboratories, Research Institutions, Pharmaceutical Companies), By Product Type (Consumables, Instruments, Software) andBy Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2026-2035

CAGR

8.30%

2025 Market Size

USD 1.46 Billion (2025)

2035 Market Size

USD 3.24 Billion (2035)

Healthcare ● Updated August 2026 Report ID: MRFR/HC/40925-HCR | Pages: 200 | Author: Satyendra Maurya, Rahul Gotadki

Summary Table of Contents Segmentation Methodology Download PDF

1 Market Overview |
1. 1.1 Study Assumptions & Market Definition |
2. 1.2 Scope of the Study |
3. 1.3 Research Methodology
2 Market Summary & Key Takeaways
3 Market Dynamics |
1. 3.1 Market Drivers Analysis | |
  1. 3.1.1 Precision-Medicine and Pharmacogenomic Integration | |
  2. 3.1.2 FDA Phased Laboratory-Developed Test Oversight | |
  3. 3.1.3 Organ-Transplant Volume Growth | |
  4. 3.1.4 Core-Lab Automation and High-Throughput Consolidation | |
  5. 3.1.5 Biosensor and Continuous-Monitoring Innovation | |
  6. 3.1.6 Decentralized Clinical-Trial Expansion | |
  7. 3.1.7 Emerging-Market Hospital Infrastructure Investment |
2. 3.2 Market Restraints Analysis | |
  1. 3.2.1 Capital Constraints Limiting LC-MS/MS Adoption | |
  2. 3.2.2 Reimbursement Gaps for Novel Assay Panels | |
  3. 3.2.3 Shortage of Trained Laboratory Personnel | |
  4. 3.2.4 Assay Standardization and Inter-Lab Variability | |
  5. 3.2.5 Data-Privacy Barriers for Cloud-Based TDM Platforms |
3. 3.3 Market Opportunity Analysis | |
  1. 3.3.1 Continuous Biosensor Platforms for Outpatient Monitoring | |
  2. 3.3.2 Oncology Therapeutic Drug Monitoring Expansion | |
  3. 3.3.3 Point-of-Care Testing in Low-Resource Settings | |
  4. 3.3.4 AI-Driven Dosing Decision Support and Data Monetization | |
  5. 3.3.5 Decentralized Clinical-Trial Drug Monitoring
4 Global Therapeutic Drug Monitoring Market Size & Forecast (2021–2035) |
1. 4.1 Historical Market Size (2021–2025) |
2. 4.2 Current & Forecast Market Size (2026–2035) |
3. 4.3 Market Size by Revenue (USD Billion) |
4. 4.4 Year-over-Year Growth Analysis
5 Segmentation Analysis |
1. 5.1 By Technology | |
  1. 5.1.1 Immunoassays | |
  2. 5.1.2 Chromatography / Mass Spectrometry | |
  3. 5.1.3 Biosensor-Based Platforms | |
  4. 5.1.4 Proteomic-Based Methods |
2. 5.2 By Drug Class | |
  1. 5.2.1 Antiepileptic Drugs | |
  2. 5.2.2 Immunosuppressants | |
  3. 5.2.3 Antiarrhythmic Drugs | |
  4. 5.2.4 Oncology Therapeutics | |
  5. 5.2.5 Antibiotics | |
  6. 5.2.6 Others (Psychotropics, Antiretrovirals) |
3. 5.3 By End User | |
  1. 5.3.1 Hospital Laboratories | |
  2. 5.3.2 Independent / Reference Laboratories | |
  3. 5.3.3 Point-of-Care Testing Sites | |
  4. 5.3.4 Academic & Research Institutions
6 Regional Analysis |
1. 6.1 North America | |
  1. 6.1.1 United States | |
  2. 6.1.2 Canada | |
  3. 6.1.3 Mexico |
2. 6.2 Europe | |
  1. 6.2.1 Germany | |
  2. 6.2.2 United Kingdom | |
  3. 6.2.3 France | |
  4. 6.2.4 Italy | |
  5. 6.2.5 Spain | |
  6. 6.2.6 Nordic Countries | |
  7. 6.2.7 Russia | |
  8. 6.2.8 Rest of Europe |
3. 6.3 Asia-Pacific | |
  1. 6.3.1 China | |
  2. 6.3.2 India | |
  3. 6.3.3 Japan | |
  4. 6.3.4 South Korea | |
  5. 6.3.5 ASEAN | |
  6. 6.3.6 Rest of Asia-Pacific |
4. 6.4 South America | |
  1. 6.4.1 Brazil | |
  2. 6.4.2 Argentina | |
  3. 6.4.3 Rest of South America |
5. 6.5 Middle East & Africa | |
  1. 6.5.1 Saudi Arabia | |
  2. 6.5.2 UAE | |
  3. 6.5.3 South Africa | |
  4. 6.5.4 Egypt | |
  5. 6.5.5 Rest of MEA
7 Competitive Landscape |
1. 7.1 Market Share Analysis (2025) |
2. 7.2 Competitive Benchmarking Matrix |
3. 7.3 Company Profiles | |
  1. 7.3.1 Roche Diagnostics | |
  2. 7.3.2 Abbott Laboratories | |
  3. 7.3.3 Siemens Healthineers | |
  4. 7.3.4 Thermo Fisher Scientific | |
  5. 7.3.5 Danaher (Beckman Coulter) | |
  6. 7.3.6 Bio-Rad Laboratories | |
  7. 7.3.7 bioMérieux | |
  8. 7.3.8 Sekisui Diagnostics | |
  9. 7.3.9 ARK Diagnostics | |
  10. 7.3.10 Ortho Clinical Diagnostics
8 Future Outlook & Strategic Recommendations (2026–2035) |
1. 8.1 AI-Augmented Pharmacokinetic Modeling |
2. 8.2 Decentralized and Home-Based Drug Monitoring |
3. 8.3 Biologics and Biosimilar Monitoring Mandates |
4. 8.4 Sustainability and Green-Lab Initiatives
9 Recent Developments & News
10 Frequently Asked Questions (FAQs)
11 Report Scope & Methodology |
1. 11.1 Study Period & Base Year |
2. 11.2 Data Sources & Citations |
3. 11.3 Abbreviations
12 LIST OF TABLES |
TABLE 1 Global Therapeutic Drug Monitoring Market Size & Forecast, by Revenue (USD Billion), 2021–2035 |
TABLE 2 Global Therapeutic Drug Monitoring Market – Year-over-Year Growth Analysis, 2021–2035 |
TABLE 3 Global Therapeutic Drug Monitoring Market – Driver Impact Analysis |
TABLE 4 Global Therapeutic Drug Monitoring Market – Restraint Impact Analysis |
TABLE 5 Global Therapeutic Drug Monitoring Market Size, by Technology, 2021–2035 (USD Billion) |
TABLE 6 Global Therapeutic Drug Monitoring Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 7 Global Therapeutic Drug Monitoring Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 8 Global Therapeutic Drug Monitoring Market Size, by Region, 2021–2035 (USD Billion) |
TABLE 9 North America Therapeutic Drug Monitoring Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 10 Europe Therapeutic Drug Monitoring Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 11 Asia-Pacific Therapeutic Drug Monitoring Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 12 South America Therapeutic Drug Monitoring Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 13 Middle East & Africa Therapeutic Drug Monitoring Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 14 Competitive Benchmarking Matrix – Global Therapeutic Drug Monitoring Market, 2025 |
TABLE 15 Company Profiles – Key Players, Global Therapeutic Drug Monitoring Market |
TABLE 16 Recent Developments & Strategic Announcements, 2023–2025 |
TABLE 17 Report Scope & Methodology Summary |
TABLE 18 Detailed Sources and Citations |
TABLE 19 North America Therapeutic Drug Monitoring Market Size, by Technology, 2021–2035 (USD Billion) |
TABLE 20 North America Therapeutic Drug Monitoring Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 21 North America Therapeutic Drug Monitoring Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 22 Europe Therapeutic Drug Monitoring Market Size, by Technology, 2021–2035 (USD Billion) |
TABLE 23 Europe Therapeutic Drug Monitoring Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 24 Europe Therapeutic Drug Monitoring Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 25 Asia-Pacific Therapeutic Drug Monitoring Market Size, by Technology, 2021–2035 (USD Billion) |
TABLE 26 Asia-Pacific Therapeutic Drug Monitoring Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 27 Asia-Pacific Therapeutic Drug Monitoring Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 28 South America Therapeutic Drug Monitoring Market Size, by Technology, 2021–2035 (USD Billion) |
TABLE 29 South America Therapeutic Drug Monitoring Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 30 South America Therapeutic Drug Monitoring Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 31 Middle East & Africa Therapeutic Drug Monitoring Market Size, by Technology, 2021–2035 (USD Billion) |
TABLE 32 Middle East & Africa Therapeutic Drug Monitoring Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 33 Middle East & Africa Therapeutic Drug Monitoring Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 34 United States Therapeutic Drug Monitoring Market Size, by Technology, 2021–2035 (USD Billion) |
TABLE 35 United States Therapeutic Drug Monitoring Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 36 United States Therapeutic Drug Monitoring Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 37 Canada Therapeutic Drug Monitoring Market Size, by Technology, 2021–2035 (USD Billion) |
TABLE 38 Canada Therapeutic Drug Monitoring Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 39 Canada Therapeutic Drug Monitoring Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 40 Mexico Therapeutic Drug Monitoring Market Size, by Technology, 2021–2035 (USD Billion) |
TABLE 41 Mexico Therapeutic Drug Monitoring Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 42 Mexico Therapeutic Drug Monitoring Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 43 Germany Therapeutic Drug Monitoring Market Size, by Technology, 2021–2035 (USD Billion) |
TABLE 44 Germany Therapeutic Drug Monitoring Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 45 Germany Therapeutic Drug Monitoring Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 46 United Kingdom Therapeutic Drug Monitoring Market Size, by Technology, 2021–2035 (USD Billion) |
TABLE 47 United Kingdom Therapeutic Drug Monitoring Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 48 United Kingdom Therapeutic Drug Monitoring Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 49 France Therapeutic Drug Monitoring Market Size, by Technology, 2021–2035 (USD Billion) |
TABLE 50 France Therapeutic Drug Monitoring Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 51 France Therapeutic Drug Monitoring Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 52 Italy Therapeutic Drug Monitoring Market Size, by Technology, 2021–2035 (USD Billion) |
TABLE 53 Italy Therapeutic Drug Monitoring Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 54 Italy Therapeutic Drug Monitoring Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 55 Spain Therapeutic Drug Monitoring Market Size, by Technology, 2021–2035 (USD Billion) |
TABLE 56 Spain Therapeutic Drug Monitoring Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 57 Spain Therapeutic Drug Monitoring Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 58 China Therapeutic Drug Monitoring Market Size, by Technology, 2021–2035 (USD Billion) |
TABLE 59 China Therapeutic Drug Monitoring Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 60 China Therapeutic Drug Monitoring Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 61 India Therapeutic Drug Monitoring Market Size, by Technology, 2021–2035 (USD Billion) |
TABLE 62 India Therapeutic Drug Monitoring Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 63 India Therapeutic Drug Monitoring Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 64 Japan Therapeutic Drug Monitoring Market Size, by Technology, 2021–2035 (USD Billion) |
TABLE 65 Japan Therapeutic Drug Monitoring Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 66 Japan Therapeutic Drug Monitoring Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 67 South Korea Therapeutic Drug Monitoring Market Size, by Technology, 2021–2035 (USD Billion) |
TABLE 68 South Korea Therapeutic Drug Monitoring Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 69 South Korea Therapeutic Drug Monitoring Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 70 Brazil Therapeutic Drug Monitoring Market Size, by Technology, 2021–2035 (USD Billion) |
TABLE 71 Brazil Therapeutic Drug Monitoring Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 72 Brazil Therapeutic Drug Monitoring Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 73 Saudi Arabia Therapeutic Drug Monitoring Market Size, by Technology, 2021–2035 (USD Billion) |
TABLE 74 Saudi Arabia Therapeutic Drug Monitoring Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 75 Saudi Arabia Therapeutic Drug Monitoring Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 76 UAE Therapeutic Drug Monitoring Market Size, by Technology, 2021–2035 (USD Billion) |
TABLE 77 UAE Therapeutic Drug Monitoring Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 78 UAE Therapeutic Drug Monitoring Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 79 South Africa Therapeutic Drug Monitoring Market Size, by Technology, 2021–2035 (USD Billion) |
TABLE 80 South Africa Therapeutic Drug Monitoring Market Size, by Drug Class, 2021–2035 (USD Billion) |
TABLE 81 South Africa Therapeutic Drug Monitoring Market Size, by End User, 2021–2035 (USD Billion)
13 LIST OF FIGURES |
FIGURE 1 Therapeutic Drug Monitoring Market Dynamics — Drivers, Restraints, Opportunities |
FIGURE 2 Therapeutic Drug Monitoring Market — Value Chain Analysis |
FIGURE 3 Therapeutic Drug Monitoring Market — Porter's Five Forces Analysis |
FIGURE 4 Global Therapeutic Drug Monitoring Market Size Trend & Forecast (USD Billion), 2021–2035 |
FIGURE 5 Therapeutic Drug Monitoring Market Share, by Technology (2025) |
FIGURE 6 Therapeutic Drug Monitoring Market Share, by Drug Class (2025) |
FIGURE 7 Therapeutic Drug Monitoring Market Share, by End User (2025) |
FIGURE 8 Therapeutic Drug Monitoring Market Share, by Region (2025) |
FIGURE 9 North America Therapeutic Drug Monitoring Market Size & Forecast (USD Billion), 2021–2035 |
FIGURE 10 Europe Therapeutic Drug Monitoring Market Size & Forecast (USD Billion), 2021–2035 |
FIGURE 11 Asia-Pacific Therapeutic Drug Monitoring Market Size & Forecast (USD Billion), 2021–2035 |
FIGURE 12 South America Therapeutic Drug Monitoring Market Size & Forecast (USD Billion), 2021–2035 |
FIGURE 13 Middle East & Africa Therapeutic Drug Monitoring Market Size & Forecast (USD Billion), 2021–2035 |
FIGURE 14 Therapeutic Drug Monitoring Market — Competitive Landscape Heat Map (2025) |
FIGURE 15 Therapeutic Drug Monitoring Market — Company Market Share Analysis (2025)

Certified Researchers

Customize Report

Segmentation Quick Reference

Dimension	Sub-Segments	Dominant Segment	Fastest Growing Segment
By Therapeutic Drug Monitoring Market	Immunoassays; Chromatography / Mass Spectrometry; Biosensor-Based Platforms; Proteomic-Based Methods	Immunoassays	Biosensor-Based Platforms
By Drug Class	Antiepileptic Drugs; Immunosuppressants; Antiarrhythmic Drugs; Oncology Therapeutics; Antibiotics; Others	Antiepileptic Drugs	Oncology Therapeutics
By End User	Hospital Laboratories; Independent / Reference Laboratories; Point-of-Care Testing Sites; Academic & Research Institutions	Hospital Laboratories	Point-of-Care Testing Sites

Market Segmentation Overview

By Therapeutic Drug Monitoring Market

Sub-Segment	Key Trend
Immunoassays	Core-lab automation driving consolidation onto high-throughput platforms
Chromatography / Mass Spectrometry	Multi-analyte panels are gaining traction in oncology and antiretroviral protocols.
Biosensor-Based Platforms	Wearable aptamer-based devices enabling continuous outpatient monitoring
Proteomic-Based Methods	Research-stage applications in biomarker discovery and niche clinical assays

Immunoassays continue to anchor the largest technology share due to widespread installed bases and low per-test operating costs. Biosensor-based platforms, though currently a small fraction of revenue, are attracting disproportionate R&D investment and clinical-trial activity, positioning them as the primary growth vector through 2035.

By Drug Class

Sub-Segment	Key Trend
Antiepileptic Drugs	Stable high-volume testing driven by narrow therapeutic indices
Immunosuppressants	Lifelong transplant-monitoring requirements create durable demand.
Antiarrhythmic Drugs	Aging cardiovascular populations sustain testing volumes.
Oncology Therapeutics	Expanding guidelines for kinase-inhibitor and immunotherapy monitoring
Antibiotics	Antimicrobial stewardship programs mandating vancomycin and aminoglycoside levels
Others (Psychotropics, Antiretrovirals)	Emerging clinical guidelines broadening test-menu requirements

Antiepileptic agents maintain the dominant drug-class position, but oncology therapeutics are rapidly closing the gap as international guidelines expand monitoring recommendations for targeted therapies. Immunosuppressant monitoring remains a foundational revenue pillar tied directly to transplant-activity growth.

By End User

Sub-Segment	Key Trend
Hospital Laboratories	Centralized core-lab models reinforcing volume concentration
Independent / Reference Laboratories	Esoteric and specialized assay menus are attracting outsourced testing.
Point-of-Care Testing Sites	Rapid-turnaround devices enabling outpatient and remote monitoring
Academic & Research Institutions	Clinical-trial pharmacokinetic endpoint testing is driving demand.

Hospital laboratories remain the dominant end-user channel, benefiting from proximity to prescribers and transplant teams. Point-of-care testing sites represent the fastest-growing segment as decentralization trends accelerate across transplant follow-up, antimicrobial stewardship, and decentralized clinical-trial protocols.

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”